ZA200505780B - Novel method for synthesising derivatives of (2S, 3AS, 7AS)-1-Ä(S)-alanylÜ-octahydro,-1H-indole-2-carboxylic acid and the use thereof for perindopril synthesis - Google Patents

Novel method for synthesising derivatives of (2S, 3AS, 7AS)-1-Ä(S)-alanylÜ-octahydro,-1H-indole-2-carboxylic acid and the use thereof for perindopril synthesis Download PDF

Info

Publication number: ZA200505780B
Authority: ZA; South Africa
Prior art keywords: formula; compound; yield; synthesis; amine function
Prior art date: 2003-02-28

Application number

ZA200505780A

Other languages

English (en)

Inventor

Thierry Dubuffet

Pascal Langlois

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-28

Filing date

2004-02-27

Publication date

2006-09-27

2004-02-27 Application filed by Servier Lab filed Critical Servier Lab

2006-09-27 Publication of ZA200505780B publication Critical patent/ZA200505780B/en

Links

230000015572 biosynthetic process Effects 0.000 title claims description 14
238000003786 synthesis reaction Methods 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 13
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims description 7
229960002582 perindopril Drugs 0.000 title claims description 7
150000001875 compounds Chemical class 0.000 claims description 31
230000008569 process Effects 0.000 claims description 12
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
150000001412 amines Chemical group 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
125000006239 protecting group Chemical group 0.000 claims description 6
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
-1 serine compound Chemical class 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
239000003054 catalyst Substances 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
KTZNVZJECQAMBV-UHFFFAOYSA-N 1-(cyclohexen-1-yl)pyrrolidine Chemical compound C1CCCN1C1=CCCCC1 KTZNVZJECQAMBV-UHFFFAOYSA-N 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
235000004279 alanine Nutrition 0.000 claims description 2
230000018044 dehydration Effects 0.000 claims description 2
238000006297 dehydration reaction Methods 0.000 claims description 2
238000010511 deprotection reaction Methods 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
229910052759 nickel Inorganic materials 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
229910052763 palladium Inorganic materials 0.000 claims description 2
229910052697 platinum Inorganic materials 0.000 claims description 2
238000001953 recrystallisation Methods 0.000 claims description 2
229910052703 rhodium Inorganic materials 0.000 claims description 2
239000010948 rhodium Substances 0.000 claims description 2
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
238000005984 hydrogenation reaction Methods 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
QNRXNRGSOJZINA-QMMMGPOBSA-N (2s)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-QMMMGPOBSA-N 0.000 description 1
PCVKNTCHCTVEAO-CYDGBPFRSA-N (2s,3as,7as)-1-[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C)[C@H]21 PCVKNTCHCTVEAO-CYDGBPFRSA-N 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Catalysts (AREA)

ZA200505780A 2003-02-28 2004-02-27 Novel method for synthesising derivatives of (2S, 3AS, 7AS)-1-Ä(S)-alanylÜ-octahydro,-1H-indole-2-carboxylic acid and the use thereof for perindopril synthesis ZA200505780B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03290486A EP1403277B1 (fr)	2003-02-28	2003-02-28	Nouveau procédé de synthèse de dérives de l'acide (2S, 3aS, 7aS)-1-((S)-alanyl)-octahydro-1H-indole-2-carboxylique, et application à la synthèse du perindopril

Publications (1)

Publication Number	Publication Date
ZA200505780B true ZA200505780B (en)	2006-09-27

Family

ID=31970534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200505780A ZA200505780B (en)	2003-02-28	2004-02-27	Novel method for synthesising derivatives of (2S, 3AS, 7AS)-1-Ä(S)-alanylÜ-octahydro,-1H-indole-2-carboxylic acid and the use thereof for perindopril synthesis

Country Status (19)

Country	Link
US (1)	US7157485B2 (da)
EP (1)	EP1403277B1 (da)
JP (1)	JP4279871B2 (da)
CN (1)	CN1331883C (da)
AR (1)	AR043410A1 (da)
AT (1)	ATE305939T1 (da)
AU (1)	AU2004218202B2 (da)
DE (1)	DE60301774T2 (da)
DK (1)	DK1403277T3 (da)
EA (1)	EA009062B1 (da)
ES (1)	ES2249691T3 (da)
HK (1)	HK1086280A1 (da)
MY (1)	MY136851A (da)
NZ (1)	NZ541423A (da)
PL (1)	PL211506B1 (da)
PT (1)	PT1403277E (da)
SI (1)	SI1403277T1 (da)
WO (1)	WO2004078708A2 (da)
ZA (1)	ZA200505780B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1403277T1 (sl) *	2003-02-28	2005-12-31	Servier Lab	NOV POSTOPEK ZA SINTEZO DERIVATOV (2S, 3aS, 7aS)-1-((S)-ALANIL)-OKTAHIDRO-1H-INDOL-2-KARBOKSILNE KISLINE IN UPORABA PRI SINTEZI PERINDOPRILA
ES2250847T3 (es) *	2003-02-28	2006-04-16	Les Laboratoires Servier	Nuevo procedimiento de sintesis del acido (2s,3as,7as)-perhidroindol-2-carboxilico y sus eteres y su aplicacion a la sintesis de perindropil.
SI2200981T1 (sl) *	2007-10-17	2012-03-30	Dsm Sinochem Pharm Nl Bv	Novi derivati karbamoilglicina
WO2009098251A1 (en) *	2008-02-07	2009-08-13	Dsm Ip Assets B.V.	NOVEL CYCLOALKANONE β-SUBSTITUTED ALANINE DERIVATIVES
WO2011133651A1 (en) *	2010-04-20	2011-10-27	Chiral Quest , Inc.	An enantioselective process for cycloalkenyl b-substituted alanines
CN106657507B (zh) *	2015-11-03	2019-07-02	中移（杭州）信息技术有限公司	一种声学回声消除方法及装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202903A (en) *	1981-12-29	1988-01-08	Hoechst Ag	1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions
NL1008302C2 (nl) *	1998-02-13	1999-08-16	Dsm Nv	Werkwijze voor de bereiding van een optisch actief indoline-2-carbonzuur of derivaat daarvan.
WO2001016336A1 (en) *	1999-09-02	2001-03-08	Lexicon Genetics Incorporated	Human calcium dependent proteases and polynucleotides encoding the same
FR2807431B1 (fr) *	2000-04-06	2002-07-19	Adir	Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2827860B1 (fr) *	2001-07-24	2004-12-10	Servier Lab	Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
SI1403277T1 (sl) *	2003-02-28	2005-12-31	Servier Lab	NOV POSTOPEK ZA SINTEZO DERIVATOV (2S, 3aS, 7aS)-1-((S)-ALANIL)-OKTAHIDRO-1H-INDOL-2-KARBOKSILNE KISLINE IN UPORABA PRI SINTEZI PERINDOPRILA

2003
- 2003-02-28 SI SI200330092T patent/SI1403277T1/sl unknown
- 2003-02-28 ES ES03290486T patent/ES2249691T3/es not_active Expired - Lifetime
- 2003-02-28 DK DK03290486T patent/DK1403277T3/da active
- 2003-02-28 PT PT03290486T patent/PT1403277E/pt unknown
- 2003-02-28 AT AT03290486T patent/ATE305939T1/de active
- 2003-02-28 DE DE60301774T patent/DE60301774T2/de not_active Expired - Lifetime
- 2003-02-28 EP EP03290486A patent/EP1403277B1/fr not_active Expired - Lifetime
2004
- 2004-02-27 AR ARP040100610A patent/AR043410A1/es not_active Application Discontinuation
- 2004-02-27 NZ NZ541423A patent/NZ541423A/en not_active IP Right Cessation
- 2004-02-27 EA EA200501257A patent/EA009062B1/ru not_active IP Right Cessation
- 2004-02-27 ZA ZA200505780A patent/ZA200505780B/en unknown
- 2004-02-27 JP JP2006500162A patent/JP4279871B2/ja not_active Expired - Fee Related
- 2004-02-27 WO PCT/FR2004/000445 patent/WO2004078708A2/fr active Application Filing
- 2004-02-27 PL PL377220A patent/PL211506B1/pl unknown
- 2004-02-27 CN CNB2004800054063A patent/CN1331883C/zh not_active Expired - Fee Related
- 2004-02-27 MY MYPI20040681A patent/MY136851A/en unknown
- 2004-02-27 US US10/547,132 patent/US7157485B2/en not_active Expired - Fee Related
- 2004-02-27 AU AU2004218202A patent/AU2004218202B2/en not_active Ceased
2006
- 2006-05-29 HK HK06106194A patent/HK1086280A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2006519176A (ja)	2006-08-24
US20060149082A1 (en)	2006-07-06
DE60301774T2 (de)	2006-07-20
EP1403277B1 (fr)	2005-10-05
WO2004078708A3 (fr)	2004-10-14
DK1403277T3 (da)	2005-11-21
AR043410A1 (es)	2005-07-27
ATE305939T1 (de)	2005-10-15
CN1753907A (zh)	2006-03-29
PL211506B1 (pl)	2012-05-31
ES2249691T3 (es)	2006-04-01
PT1403277E (pt)	2005-11-30
EA009062B1 (ru)	2007-10-26
JP4279871B2 (ja)	2009-06-17
NZ541423A (en)	2008-03-28
AU2004218202A1 (en)	2004-09-16
AU2004218202B2 (en)	2009-07-30
SI1403277T1 (sl)	2005-12-31
MY136851A (en)	2008-11-28
US7157485B2 (en)	2007-01-02
CN1331883C (zh)	2007-08-15
WO2004078708A2 (fr)	2004-09-16
EA200501257A1 (ru)	2006-04-28
HK1086280A1 (en)	2006-09-15
PL377220A1 (pl)	2006-01-23
DE60301774D1 (de)	2006-02-16
EP1403277A1 (fr)	2004-03-31

Publication	Publication Date	Title
KR100607556B1 (ko)	2006-08-02	(2Ｓ, 3ａＳ,7ａＳ)-1-[(Ｓ)-알라닐]-옥타히드로-1Ｈ-인돌-2-카르복실산유도체의 신규한 합성 방법 및 페린도프릴 합성에서의이의 용도
AU2004218202B2 (en)	2009-07-30	Novel method for synthesising derivatives of (2S, 3aS, 7aS)-1-[(S)-alanyl]-octahydro,-IH-indole-2-carboxylic acid and the use thereof for perindopril synthesis
AU2004270429B2 (en)	2007-05-24	Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
US20070043103A1 (en)	2007-02-22	Novel metod for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
AU2004218200B2 (en)	2009-07-30	Novel method for synthesising (2S, 3aS, 7aS)-perhydroindole-2-carboxylic acid and the esters thereof and the use thereof for perindopril synthesis
AU2004217599B2 (en)	2009-07-30	Novel method for synthesising perindopril and the pharmaceutically acceptable salt thereof
EP1319668B1 (fr)	2004-10-27	Nouveau procédé de synthèse de dérivés de l'acide (2S, 3aS, 7aS)-1-[(S)]-alanyl]-octahydro-1H-indole-2-carboxylique et application à la synthèse du perindopril
ZA200601429B (en)	2007-05-30	Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof